Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic : rapid review
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVE: To appraise the availability, quality, and inclusivity of clinical guidelines produced in the early stage of the coronavirus disease 2019 (covid-19) pandemic.
DESIGN: Rapid review.
DATA SOURCES: Ovid Medline, Ovid Embase, Ovid Global Health, Scopus, Web of Science Core Collection, and WHO Global Index Medicus, searched from inception to 14 Mar 2020. Search strategies applied the CADTH database guidelines search filter, with no limits applied to search results. Further studies were identified through searches of grey literature using the ISARIC network.
INCLUSION CRITERIA: Clinical guidelines for the management of covid-19, Middle East respiratory syndrome (MERS), and severe acute respiratory syndrome (SARS) produced by international and national scientific organisations and government and non-governmental organisations relating to global health were included, with no exclusions for language. Regional/hospital guidelines were excluded. Only the earliest version of any guideline was included.
QUALITY ASSESSMENT: Quality was assessed using the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool. The quality and contents of early covid-19 guidelines were also compared with recent clinical guidelines for MERS and SARS.
RESULTS: 2836 studies were identified, of which 2794 were excluded after screening. Forty two guidelines were considered eligible for inclusion, with 18 being specific to covid-19. Overall, the clinical guidelines lacked detail and covered a narrow range of topics. Recommendations varied in relation to, for example, the use of antiviral drugs. The overall quality was poor, particularly in the domains of stakeholder involvement, applicability, and editorial independence. Links between evidence and recommendations were limited. Minimal provision was made for vulnerable groups such as pregnant women, children, and older people.
CONCLUSIONS: Guidelines available early in the covid-19 pandemic had methodological weaknesses and neglected vulnerable groups such as older people. A framework for development of clinical guidelines during public health emergencies is needed to ensure rigorous methods and the inclusion of vulnerable populations.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020167361.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:369 |
|---|---|
| Enthalten in: |
BMJ (Clinical research ed.) - 369(2020) vom: 26. Mai, Seite m1936 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dagens, Andrew [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 02.06.2020 Date Revised 11.11.2023 published: Electronic ErratumIn: BMJ. 2020 Jun 12;369:m2371. - PMID 32532740 Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmj.m1936 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310390486 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310390486 | ||
| 003 | DE-627 | ||
| 005 | 20231225140004.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmj.m1936 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1034.xml |
| 035 | |a (DE-627)NLM310390486 | ||
| 035 | |a (NLM)32457027 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dagens, Andrew |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic |b rapid review |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.06.2020 | ||
| 500 | |a Date Revised 11.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ErratumIn: BMJ. 2020 Jun 12;369:m2371. - PMID 32532740 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVE: To appraise the availability, quality, and inclusivity of clinical guidelines produced in the early stage of the coronavirus disease 2019 (covid-19) pandemic | ||
| 520 | |a DESIGN: Rapid review | ||
| 520 | |a DATA SOURCES: Ovid Medline, Ovid Embase, Ovid Global Health, Scopus, Web of Science Core Collection, and WHO Global Index Medicus, searched from inception to 14 Mar 2020. Search strategies applied the CADTH database guidelines search filter, with no limits applied to search results. Further studies were identified through searches of grey literature using the ISARIC network | ||
| 520 | |a INCLUSION CRITERIA: Clinical guidelines for the management of covid-19, Middle East respiratory syndrome (MERS), and severe acute respiratory syndrome (SARS) produced by international and national scientific organisations and government and non-governmental organisations relating to global health were included, with no exclusions for language. Regional/hospital guidelines were excluded. Only the earliest version of any guideline was included | ||
| 520 | |a QUALITY ASSESSMENT: Quality was assessed using the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool. The quality and contents of early covid-19 guidelines were also compared with recent clinical guidelines for MERS and SARS | ||
| 520 | |a RESULTS: 2836 studies were identified, of which 2794 were excluded after screening. Forty two guidelines were considered eligible for inclusion, with 18 being specific to covid-19. Overall, the clinical guidelines lacked detail and covered a narrow range of topics. Recommendations varied in relation to, for example, the use of antiviral drugs. The overall quality was poor, particularly in the domains of stakeholder involvement, applicability, and editorial independence. Links between evidence and recommendations were limited. Minimal provision was made for vulnerable groups such as pregnant women, children, and older people | ||
| 520 | |a CONCLUSIONS: Guidelines available early in the covid-19 pandemic had methodological weaknesses and neglected vulnerable groups such as older people. A framework for development of clinical guidelines during public health emergencies is needed to ensure rigorous methods and the inclusion of vulnerable populations | ||
| 520 | |a SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020167361 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Sigfrid, Louise |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Erhui |e verfasserin |4 aut | |
| 700 | 1 | |a Lipworth, Sam |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Harris, Eli |e verfasserin |4 aut | |
| 700 | 1 | |a Bannister, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Rigby, Ishmeala |e verfasserin |4 aut | |
| 700 | 1 | |a Horby, Peter |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ (Clinical research ed.) |d 1988 |g 369(2020) vom: 26. Mai, Seite m1936 |w (DE-627)NLM012612685 |x 1756-1833 |7 nnns |
| 773 | 1 | 8 | |g volume:369 |g year:2020 |g day:26 |g month:05 |g pages:m1936 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmj.m1936 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 369 |j 2020 |b 26 |c 05 |h m1936 | ||